SB1246 directs the Hawaii Department of Health to purchase and store a one-year supply of mifepristone, working with one or more pharmacies located in the state. The bill is framed as a response to post-Dobbs legal uncertainty and to Hawaii’s longstanding constitutional and statutory protections for privacy, bodily autonomy, and reproductive decision-making. It cites the state’s history of abortion access, the 2006 law protecting abortion rights, and concerns that other states may try to impose liability on people who obtain or assist with reproductive health care outside their borders.
The measure also appropriates general funds for fiscal year 2025-2026 to pay for the stockpile, with the amount left blank in the bill text. It specifies that the supply should be maintained by the Department of Health and notes that mifepristone has a five-year shelf life. The bill’s effective date is set far in the future, December 31, 2050, which appears to be a placeholder or delayed effective date rather than an immediate operational date.
Impact
If enacted, SB1246 would add a new state obligation for the Department of Health to procure and store mifepristone as a reproductive health care reserve, using local pharmacies as purchasing partners. It would create a direct state expenditure from general revenues and could influence how Hawaii maintains access to medication abortion, especially if supply chains are disrupted or federal regulatory conditions change. The bill does not amend existing abortion statutes directly, but it reinforces Hawaii’s policy framework protecting reproductive rights and could affect public health procurement practices and pharmacy-state coordination.
Sentiment
The available voting history suggests generally favorable committee sentiment: the Senate Health and Human Services Committee passed the bill with amendments by a 4-0 vote on January 31, 2025. The bill text itself is strongly supportive of abortion access and reproductive autonomy, and its findings emphasize Hawaii’s historical role in protecting privacy and abortion rights. No committee transcript was provided, so the record here shows support in committee but does not reveal broader floor debate or public testimony.
Contention
The main points of contention are likely to center on abortion policy, state spending, and whether Hawaii should stockpile a medication used for abortion in anticipation of legal or supply disruptions. Supporters would view the bill as a preventive measure to preserve access to medication abortion and protect residents from out-of-state restrictions or supply-chain problems. Opponents would likely object on moral, political, or fiscal grounds, particularly to the use of public funds to purchase mifepristone and to the bill’s explicit endorsement of abortion access. The bill also raises practical questions about storage, procurement, and the role of the Department of Health in maintaining the stockpile.